Inclusion Criteria:

          -  Advanced solid tumor

          -  Measurable disease, per RECIST v1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Adequate organ function

        Exclusion Criteria:

          -  Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade ≤1] from the
             acute toxicities of previous therapy, except treatment-related alopecia or laboratory
             abnormalities otherwise meeting eligibility requirements

          -  Received prior chemotherapeutic, investigational, or other therapies for the treatment
             of cancer within 14 days with small molecule and within 28 days with biologic before
             the first dose of UCT-01-097

          -  Progressive or symptomatic brain metastases

          -  Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active,
             uncontrolled infection

          -  History of phosphate or calcium disorder

          -  History of significant cardiac disease

          -  History or current evidence/risk of retinopathy

          -  History of myelodysplastic syndrome (MDS) or AML

          -  History of another cancer within 3 years before Day 1 of study treatment, with the
             exception of basal or squamous cell carcinoma of the skin that has been definitively
             treated. A history of other malignancies with a low risk of recurrence, including
             appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate
             cancer with a Gleason score less than or equal to 6, are also not excluded

          -  If female, is pregnant or breastfeeding